Magazine Article | May 3, 2021

A Q&A With A COVID-Era New CEO

Source: Life Science Leader

By Dan Schell, Editorial Director, Life Science Leader

Becoming the CEO of a pharma company early in the COVID pandemic would be a big challenge for even a seasoned executive in this industry. Just ask David Horn Solomon, Ph.D., who took on the top role at Pharnext in April 2020. But for him, the challenge was two-fold, because the company recently had its Phase 3 trial data rejected by the FDA (for more on this part of the story, read my colleague Ed Miseta’s article on Clinical Leader called, “A Clinical Setback Leads To A Transformation And A New Trial”). We caught up with Solomon in February 2021 to see what he has accomplished so far as he approaches one year on the job.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: